Bank of Montreal Can Acquires 18,213 Shares of Elanco Animal Health Incorporated $ELAN

Bank of Montreal Can boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 19.5% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 111,496 shares of the company’s stock after buying an additional 18,213 shares during the period. Bank of Montreal Can’s holdings in Elanco Animal Health were worth $1,592,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ELAN. HighTower Advisors LLC boosted its stake in shares of Elanco Animal Health by 7.0% during the 1st quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock worth $131,000 after acquiring an additional 810 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Elanco Animal Health by 8.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company’s stock worth $169,000 after purchasing an additional 944 shares during the last quarter. Graypoint LLC lifted its holdings in Elanco Animal Health by 4.9% in the 1st quarter. Graypoint LLC now owns 26,845 shares of the company’s stock worth $282,000 after purchasing an additional 1,256 shares during the last quarter. Commerce Bank boosted its position in Elanco Animal Health by 3.7% during the first quarter. Commerce Bank now owns 35,321 shares of the company’s stock worth $371,000 after purchasing an additional 1,256 shares during the period. Finally, Probity Advisors Inc. grew its holdings in Elanco Animal Health by 10.0% during the first quarter. Probity Advisors Inc. now owns 14,520 shares of the company’s stock valued at $152,000 after purchasing an additional 1,314 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $22.01 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. The company has a market cap of $10.94 billion, a PE ratio of 366.89, a price-to-earnings-growth ratio of 3.00 and a beta of 1.71. The firm has a fifty day moving average price of $20.53 and a two-hundred day moving average price of $16.53. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $23.09.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the prior year, the business earned $0.13 earnings per share. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ELAN. Piper Sandler boosted their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, August 11th. Stifel Nicolaus boosted their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Leerink Partners upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target for the company in a report on Thursday, July 17th. Zacks Research downgraded Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Finally, Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Elanco Animal Health currently has an average rating of “Moderate Buy” and a consensus target price of $20.29.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.